R. S. Herbst Et Al. , "Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC," NEW ENGLAND JOURNAL OF MEDICINE , vol.383, no.14, pp.1328-1339, 2020
Herbst, R. S. Et Al. 2020. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. NEW ENGLAND JOURNAL OF MEDICINE , vol.383, no.14 , 1328-1339.
Herbst, R. S., Giaccone, G., de Marinis, F., Reinmuth, N., Vergnenegre, A., Barrios, C. H., ... Morise, M.(2020). Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. NEW ENGLAND JOURNAL OF MEDICINE , vol.383, no.14, 1328-1339.
Herbst, Roy Et Al. "Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC," NEW ENGLAND JOURNAL OF MEDICINE , vol.383, no.14, 1328-1339, 2020
Herbst, Roy S. Et Al. "Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC." NEW ENGLAND JOURNAL OF MEDICINE , vol.383, no.14, pp.1328-1339, 2020
Herbst, R. S. Et Al. (2020) . "Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC." NEW ENGLAND JOURNAL OF MEDICINE , vol.383, no.14, pp.1328-1339.
@article{article, author={Roy S. Herbst Et Al. }, title={Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC}, journal={NEW ENGLAND JOURNAL OF MEDICINE}, year=2020, pages={1328-1339} }